Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis

Annals of Neurology

Volumn 73, Issue 6, 2013, Pages 705-713

  Khan, Omar ^a   Rieckmann, Peter ^b   Boyko, Alexey ^c   Selmaj, Krzysztof ^d   Zivadinov, Robert ^e  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; GLATIRAMER; PLACEBO;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EXPANDED DISABILITY STATUS SCALE; FEMALE; FEVER; FLUSHING; HEADACHE; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPEREMIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCULOSKELETAL CHEST PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RHINOPHARYNGITIS; RISK REDUCTION; SCREENING; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84881226959     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23938     Document Type: Article

References (17)

1. Kala M, Miravalle A, Vollmer T,. Recent insights into the mechanism of action of glatiramer acetate. J Immunol 2011; 235: 9-17.
2. Aharoni R,. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev 2013; 12: 543-553.
3. Racke MK,., Lovett-Racke AE,. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. J Immunol 2011; 186: 1887-1890
4. Milo R, Kahana E,. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010; 9: A387-A394.
5. TEVA Pharmaceuticals USA. Copaxone (glatiramer acetate) prescribing information. February 2009. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/020622s057lbl.pdf. Accessed February 4, 2013.
6. Lalive PH, Nauhaus O, Benkhoucha M, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 2011; 25: 401-414.
7. Weber MS, Hohlfled R, Zamvil SS,. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007; 4: 647-653.
8. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-1276.
9. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317: 408-414.
10. Comi G, Filippi M, Wolinsky JS,. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-297.
11. Boneschi F, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler 2003; 9: 349-355.
12. Comi G, Martinelli V, Rodegher M, et al. PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503-1511.
13. Comi G, Cohen JA, Arnold DL, et al. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol 2011; 69: 75-82.
14. Khan O, Caon C, Zak I, et al. Randomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every-other-day galtiramer acetate 20 mg subcutaneous injections in relapsing-remitting multiple sclerosis. Mult Scler 2008; 14 (suppl 1): S296.
15. Khan O, Perumal J, Caon C, et al. Glatiramer acetate 20mg subcutaneous twice-weekly versus daily injections: results of a pilot, prospective, randomised, and rater-blinded clinical and MRI 2-year study in relapsing-remitting multiple sclerosis. Mult Scler 2009; 15 (suppl 2): S249-S250.
16. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005; 58: 840-846.
17. Cohen JA, Rovaris M, Goodman AD, et al. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting multiple sclerosis. Neurology 2007; 68: 939-944.